GOTHENBURG, SWEDEN / ACCESSWIRE / January 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report 2024. The presentation will be held in English.
Time: Tuesday, January 28, 2025, at 2.00 pm CET / 8.00 am EST
If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions. https://xvivo.events.inderes.com/xvivo-q4-report-2024
If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. Via the teleconference you can ask questions verbally. https://conference.inderes.com/teleconference/?id=5003998
Participants from XVIVO:
Christoffer Rosenblad, CEO
Kristoffer Nordström, CFO
The press release for XVIVO's Year-end Report 2024 will be released on January 28, 2025 at 7.30 am CET / 1.30 am EST.
Before the conference call, slides will be available at the company web page, https://www.xvivogroup.com/investors/reports-and-presentations/
January 13, 2025
Mölndal
XVIVO Perfusion AB (publ)
For further information, please contact:
Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq Stockholm under the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
Attachments
Conference call on Year-end Report 2024
SOURCE: XVIVO Perfusion AB
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。